...
首页> 外文期刊>Modern Pathology >Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung
【24h】

Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung

机译:核galectin-3表达是肺腺癌和鳞状细胞癌复发的独立预测因素

获取原文
           

摘要

The tumor stage is the most powerful prognostic tool for predicting the survival rates of lung carcinoma patients. However, prognosis of individual patients is difficult in part because of the marked clinical heterogeneity among such patients. Galectins are involved in cell growth, apoptosis and cell migration features, and their diagnostic and prognostic values have already been demonstrated in various types of cancers. In the present paper we analyze the potential prognostic value of immunohistochemical galectin-3 expression in lung adenocarcinomas and squamous cell carcinomas. In all, 165 squamous cell carcinomas and 121 adenocarcinomas were immunostained for galectin-3. In each case the immunohistochemical analyses consisted of an evaluation of the percentage of tumor cells stained and the intensity of staining. An IP score (ie Intensity Percentage) was thus determined for each lung carcinoma. A large majority of cases displayed galectin-3 expression. While the cytoplasmic staining in the squamous cell carcinomas was focal and moderately intense, the staining in the adenocarcinomas was diffuse and intense. The IP scores were significantly (P=0.0001) higher in the adenocarcinomas than in the squamous cell carcinomas. The difference in nuclear expression profiles between the two cancer types was statistically significant (P=0.0005). Cox multivariate analysis carried out on the patients' genders, the TNM classification and the galectin-3-related variables showed that of the galectin-3-related variables, only the nuclear location of galectin-3 was identified as a prognostic indicator of recurrence independent of the clinicopathological features characterizing the patients (P=0.02). The prognostic contribution of this latter variable was enhanced when the patients with relapse-free follow-ups longer than 8 months were considered (P=0.005). Galectin-3 immunohistochemical expression differs between squamous cell carcinomas and adenocarcinomas, but the nuclear expression of galectin-3 behaves as a significant prognostic predictor for all the cases as a group.
机译:肿瘤分期是预测肺癌患者生存率的最有力的预后工具。但是,部分患者的预后很困难,部分原因是此类患者之间存在明显的临床异质性。半乳凝素参与细胞生长,凋亡和细胞迁移特征,其诊断和预后价值已在各种类型的癌症中得到证实。在本文中,我们分析了免疫组化galectin-3表达在肺腺癌和鳞状细胞癌中的潜在预后价值。总共对165个鳞状细胞癌和121个腺癌进行了Galectin-3免疫染色。在每种情况下,免疫组织化学分析包括对染色的肿瘤细胞的百分比和染色强度的评估。因此确定了每种肺癌的IP评分(即强度百分比)。绝大多数病例显示galectin-3表达。鳞状细胞癌的细胞质染色是局灶性和中等强度的,而腺癌的染色是弥漫性的和强烈的。腺癌的IP评分显着高于鳞状细胞癌(P = 0.0001)。两种癌症类型之间的核表达谱差异具有统计学意义(P = 0.0005)。对患者性别,TNM分类和与galectin-3相关的变量进行Cox多变量分析表明,在与galectin-3相关的变量中,只有galectin-3的核位置被确定为独立于预后的指标患者的临床病理特征(P = 0.02)。当考虑随访时间超过8个月的无复发患者时,后一个变量的预后作用得到增强(P = 0.005)。 Galectin-3的免疫组织化学表达在鳞状细胞癌和腺癌之间有所不同,但在所有病例中,galectin-3的核表达可作为重要的预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号